Abstract
Mesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
Keywords: Asbestos, epidemiology, treatment, Mesothelioma, tri-modality (surgery, radiotherapy and chemotherapy), pleural and peritoneal mesothelioma, malignant meosothelioma
Current Respiratory Medicine Reviews
Title: Mesothelioma - Epidemiology and Management
Volume: 7 Issue: 5
Author(s): Patricia Tai, Edward Yu, Avi Assouline and Kurian Joseph
Affiliation:
Keywords: Asbestos, epidemiology, treatment, Mesothelioma, tri-modality (surgery, radiotherapy and chemotherapy), pleural and peritoneal mesothelioma, malignant meosothelioma
Abstract: Mesothelioma is an uncommon tumor. It has a latency period of 20-40 years. The most important risk factor is asbestos exposure. Prognosis of mesothelioma is generally poor with high case-fatality rate, and research to improve the outcome of this disease is on-going worldwide. Due to its rarity, management by a multidisciplinary team with experience is recommended. Carefully selected patients may benefit from tri-modality (surgery, radiotherapy and chemotherapy) treatment. The management of pleural and peritoneal mesothelioma is summarized in this review. Recent advances in chemotherapy and biologic response modifiers are promising.
Export Options
About this article
Cite this article as:
Tai Patricia, Yu Edward, Assouline Avi and Joseph Kurian, Mesothelioma - Epidemiology and Management, Current Respiratory Medicine Reviews 2011; 7 (5) . https://dx.doi.org/10.2174/157339811797189731
DOI https://dx.doi.org/10.2174/157339811797189731 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Current Cancer Drug Targets Major Highlights of the CAR-TCR Summit, Boston, 2016
Anti-Cancer Agents in Medicinal Chemistry Validated RP-HPLC Method for the Simultaneous Analysis of Gemcitabine and LY-364947 in Liposomal Formulations
Current Drug Targets Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Current Drug Targets Cytokine Network: New Targeted Therapy for Pancreatic Cancer
Current Pharmaceutical Design Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks
Current Medicinal Chemistry Targeting the RAS Signaling Pathway in Malignant Hematologic Diseases
Current Drug Targets The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets The Means to an End of Tumor Cell Resistance to Chemotherapeutic Drugs Targeting Thymidylate Synthase: Shoot the Messenger
Current Drug Targets The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry To Seek Shelter from the Wnt in Osteoarthritis? Wnt-Signaling as a Target for Osteoarthritis Therapy
Current Drug Targets Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
Current Pharmaceutical Design